drugset / Trial / NCT00528502

Lidocaine Supplement for Minimal Invasive Parathyroid Surgery

NCT00528502 ↗

Phase 3 Withdrawn M.D. Anderson Cancer Center
RandomizedParallel-groupTriple-blindTreatment

Summary

Primary Objective: 1\. To determine if the application of lidocaine to the airway will obtund or abolish the laryngeal reflexes. This in turn will lead to a quiescent controlled surgical field.

Timeline

Start
2006-06
Primary completion
2008-01
Completion
2008-01

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to no patient enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified — Inhaled